FDA panel supports bolder label for Spiriva Handihaler

11/19/2009 | Google

An FDA advisory committee recommended that Boehringer Ingelheim's Spiriva Handihaler carry a revised label that includes the drug's efficacy in reducing coughing and other complications of chronic obstructive pulmonary disease. The company welcomed the decision and said it will work with the FDA through its review of the treatment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY